Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.
Iacovelli R, Ciccarese C, Brunelli M, Battelli N, Buttigliero C, Caserta C, Buti S, Santini D, Carella C, Galli L, Verri E, Ermacora P, Merler S, Masini C, De Vivo R, Milesi L, Spina F, Rizzo M, Sperduti I, Fornarini G, Tortora G. Iacovelli R, et al. Among authors: de vivo r. Ann Oncol. 2022 Nov;33(11):1179-1185. doi: 10.1016/j.annonc.2022.07.011. Epub 2022 Aug 2. Ann Oncol. 2022. PMID: 35926813 Free article. Clinical Trial.
Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study.
Maruzzo M, Pierantoni F, Bortolami A, Palleschi D, Zivi A, Nicodemo M, Sartori D, De Vivo R, Zustovich F, Bimbatti D, Pastorelli D, Vultaggio GD, Soraru' M, Ballestrin M, Modonesi C, Randisi P, Barile C, Perri G, Basso U, Zagonel V. Maruzzo M, et al. Among authors: de vivo r. Target Oncol. 2022 Jul;17(4):467-474. doi: 10.1007/s11523-022-00892-z. Epub 2022 Jun 25. Target Oncol. 2022. PMID: 35751733 Free PMC article.
Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b).
Stellato M, Santini D, Verzoni E, De Giorgi U, Pantano F, Casadei C, Fornarini G, Maruzzo M, Sbrana A, Di Lorenzo G, Soraru M, Naglieri E, Buti S, De Vivo R, Napolitano A, Vignani F, Mucciarini C, Grillone F, Roviello G, Di Napoli M, Procopio G. Stellato M, et al. Among authors: de vivo r. Front Oncol. 2021 Jun 8;11:682449. doi: 10.3389/fonc.2021.682449. eCollection 2021. Front Oncol. 2021. PMID: 34168997 Free PMC article.
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Santini D, Stellato M, De Giorgi U, Pantano F, De Lisi D, Casadei C, Maruzzo M, Bimbatti D, Naglieri E, Buti S, Bersanelli M, De Vivo R, Di Lorenzo G, Sbrana A, Verzoni E, Soraru' M, Fornarini G, Mucciarini C, Grillone F, Mini E, Vignani F, Attademo L, Pignata S, Procopio G. Santini D, et al. Among authors: de vivo r. Am J Clin Oncol. 2021 Mar 1;44(3):121-125. doi: 10.1097/COC.0000000000000791. Am J Clin Oncol. 2021. PMID: 33617179
48 results